Sprint Bioscience will be presenting previously unpublished results from the company’s DISA program targeting the protein TREX1 at the conference “Immuno-Oncology Summit Europe 2024” in London, England, 23 – 25 April 2024. The positive results from an in vivo proof-of-concept study show that treatment with the company’s TREX1 inhibitors results in an improved immune response and inhibited tumor growth.
The poster “Inhibition of TREX1 Increases Interferon Signaling and Reduces Tumor Growth In Vivo” is presented by Camilla Silvander, PhD, Director Protein Science, Sprint Bioscience.
More information about the meeting here.
